Inbakicept
Based on 2 publication(s) in Google Scholar
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: ≥99.0%
- CAS 番号: 2135939-52-3
- 分子量:66.58 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Inbakicept
More
生物活性
|
IL-15Rα |
Inbakicept (0.01-1 nM; 20 hr) enhances human NK cell cytotoxicity and increases cytotoxic effector molecule expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Daudi, Raji, CD19+ FL cells
-
Concentration:0.01 nM, 0.1 nM, and 1 nM
-
Incubation Time:20 hours
-
Result:Increased the human NK cell cytotoxicity on Daudi, Raji, CD19+ FL cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice with Daudi models[1]
-
Dosage:0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg
-
Administration:Intravenous injection; twice weekly, for 2 weeks
-
Result:Enhanced rituximab-directed control of Raji lymphoma challenge.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[IL15RA (interleukin 15 receptor subunit alpha, CD215, IL-15RA)]2-IGHG1 Fc (Fragment constant)
ELISA, FACS, Functional assay
-
Immobilized Human IL-15 Protein can bind Inbakicept. The EC50 for this effect is 50.78 ng/mL.
化学情報
-
CAS 番号 2135939-52-3
-
性状 Liquid
-
分子量 66.58 kDa
-
Color Colorless to light yellow
-
SMILES
[Inbakicept]
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
TSC22 domain family member 3 links natural killer cells to CD8+ T cell-mediated drug hypersensitivity. [Abstract]2025 Jun 21;10(1):196. PMID: 40544157 -
Cell Rep Med
Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. [Abstract]2025 Oct 21;6(10):102413. PMID: 41075789
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)